Uploaded July 2024 | Updated November 2026, 1 day ago
In this episode of "Ask the Expert, Community Spotlight Edition," Lydia Dubose of SRNA spoke with Kim Harrison about her journey with transverse myelitis (TM), adaptive sports, and challenges she has faced since her diagnosis [00:01:25]. Kim highlighted the importance of community support systems in her life [00:11:38]. She discussed managing symptoms, navigating social situations, and raising awareness for rare neuroimmune disorders [00:17:39]. Finally, Kim shared her inspiring story of completing the 500-mile Camino de Santiago in her adaptive wheelchair, demonstrating resilience and determination [00:23:49].
Originally from Atlanta, GA, Kim Harrison currently resides in St. Augustine, FL. She contracted transverse myelitis (TM) in 2004 while on a business trip to Dallas, TX. In 2012, she partitioned her State Senator, Donzella James, to declare February 15th as Transverse Myelitis Awareness Day. She is on the mayor’s accessibility committee, a United Spinal Association North Florida Chapter Advocacy Representative, a Christopher and Dana Reeve Peer Mentor, and a volunteer at Brooks Rehabilitation Hospital.
Kim organized a Walk-Run-N-Roll and has been a support group leader with SRNA. She has been on the Braves Stadium ADA advisory board, has participated in ROCH Roll on Capitol Hill with United Spinal Association, and has advocated for wheelchair users’ rights for activity based physical therapy with Warrior Momz. Kim is the adaptive athlete who rolled the 500-mile Camino de Santiago in Spain with her adaptive GRIT Freedom wheelchair. She is 65 and lives in an aged community with her husband of 38 years, Brian.
You can learn more about the organization I'll Push You and Kim's journey on the Camino de Santiago here:
accessiblecamino.com
facebook.com/groups/1051370995944241
In this episode of "Ask the Expert, Community Spotlight Edition," Lydia Dubose of SRNA spoke with Kim Harrison about her journey with transverse myelitis (TM), adaptive sports, and challenges she has faced since her diagnosis [00:01:25]. Kim highlighted the importance of community support systems in her life [00:11:38]. She discussed managing symptoms, navigating social situations, and raising awareness for rare neuroimmune disorders [00:17:39]. Finally, Kim shared her inspiring story of completing the 500-mile Camino de Santiago in her adaptive wheelchair, demonstrating resilience and determination [00:23:49].
Originally from Atlanta, GA, Kim Harrison currently resides in St. Augustine, FL. She contracted transverse myelitis (TM) in 2004 while on a business trip to Dallas, TX. In 2012, she partitioned her State Senator, Donzella James, to declare February 15th as Transverse Myelitis Awareness Day. She is on the mayor’s accessibility committee, a United Spinal Association North Florida Chapter Advocacy Representative, a Christopher and Dana Reeve Peer Mentor, and a volunteer at Brooks Rehabilitation Hospital.
Kim organized a Walk-Run-N-Roll and has been a support group leader with SRNA. She has been on the Braves Stadium ADA advisory board, has participated in ROCH Roll on Capitol Hill with United Spinal Association, and has advocated for wheelchair users’ rights for activity based physical therapy with Warrior Momz. Kim is the adaptive athlete who rolled the 500-mile Camino de Santiago in Spain with her adaptive GRIT Freedom wheelchair. She is 65 and lives in an aged community with her husband of 38 years, Brian.
You can learn more about the organization I'll Push You and Kim's journey on the Camino de Santiago here:
accessiblecamino.com
facebook.com/groups/1051370995944241
![2026 RNDS | Open Q&A: Research and Clinical Care
In this session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, moderated an open Q&A with speakers Sydney Lee, Aatqa Memon, Darina Dinov, Haiwen Chen, Linda Nguyen and Daniela Riveros Acosta, answering questions from the room and online [00:00:05]. Early questions covered molecular mimicry after infection, confidence in CAR-T therapy, and long-term spinal changes and rehabilitation after transverse myelitis [00:01:10]. The panel discussed MOG antibody disease (MOGAD) in children, how acute disseminated encephalomyelitis (ADEM) and MOGAD relate, and the cost-effectiveness of neuromyelitis optica spectrum disorder (NMOSD) treatments [00:09:02]. They then turned to MOGAD treatment options, joining CAR-T studies, and relapse risk and antibodies in NMOSD [00:18:42]. Later questions covered steroid tapers, pseudo-relapses, remyelination, and pediatric trials [00:34:20].
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He started the Neuromyelitis Optica Clinic and Research Laboratory at Johns Hopkins before moving to Massachusetts General Hospital and Harvard Medical School in 2019.
Sydney Lee, MD, was named a recipient of the James T. Lubin Clinician Scientist Fellowship Award from the Siegel Rare Neuroimmune Association. The program supports up to two years of clinical care and research training in an environment where clinicians learn to use the most current scientific tools to treat and advance knowledge about rare neuroimmune disorders.
Aatqa Memon, MD, is SRNAs 2026 James T. Lubin Fellow. She is a neuroimmunology physician at the University of Utah, listed as a Visiting Instructor in the Department of Neurologys Division of Neuroimmunology and Autoimmune Neurology, and sees patients at University of Utah Health neurology clinics in Salt Lake City.
Darina Dinov, DO, is a neurologist at Penn State University specializing in the diagnosis and treatment of diseases of the brain, spinal cord, peripheral nerves, muscles, and autonomic nervous system. She is passionate about advancing our understanding through research, education, and innovation.
Haiwen Chen, MD, is a pediatric neurologist and neuroscientist who received her medical degree from the University of Maryland and completed a Pediatrics Residency at The Johns Hopkins Hospital. She held a James T. Lubin Fellowship at Johns Hopkins University under the mentorship of Dr. Carlos Pardo. She is interested in understanding how MOGAD affects neurons and oligodendrocytes to cause neurological dysfunction.
Linda Nguyen, MD, PhD, is an Assistant Professor of Pediatrics at UT Southwestern Medical Center and Childrens Health in Dallas, Texas. She completed her MD and PhD training at West Virginia University in 2017, a pediatric neurology residency at UC San Diego in 2022, and a neuroimmunology fellowship at UT Southwestern.
Daniela Riveros Acosta, MD, is a neurologist in the Department of Neurology at Albany Medical Center, part of Albany Med Health System. She earned her medical degree at Universidad de los Andes in Bogota in 2018 and completed her neurology residency at the Icahn School of Medicine at Beth Israel Medical Center in New York. Her listed fellowship is in neuroimmunology and multiple sclerosis at Johns Hopkins University (2026).
00:00 Welcome and Panel Introductions
01:10 Molecular Mimicry After Infection
02:52 CAR-T Confidence and Complex Cases
06:09 Long-Term Spinal Changes and Rehabilitation
09:02 MOGAD in Children and ADEM
13:25 Cost-Effectiveness of NMOSD Treatments
15:37 CAR-T Trial Eligibility
18:42 Treatment Options for MOGAD
22:59 NMOSD Relapse Risk and Antibodies
28:04 Steroids and Maintenance After a New Diagnosis
32:39 Finding Research and Trials
34:20 Steroid Tapers in Children
42:45 Pseudo-Relapses
46:21 Remyelination and Pediatric Trials 2026 RNDS | Open Q&A: Research and Clinical Care](https://i.ytimg.com/vi/3rKV2ZYGFdg/mqdefault.jpg)
![Community Meets Clinic 306. Drs. Brenda Banwell and Haiwen Chen
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Drs. Brenda Banwell and Haiwen Chen of Johns Hopkins Children’s Center, a designated Center of Excellence in Rare Neuroimmune Disorders. They shared about their paths into pediatric neurology and focus on rare pediatric neuroimmune disorders [00:01:49]. They described the rapid evolution of diagnosis and treatment over the past 30 years, including advances in MS, MOGAD, and aquaporin-4 disease, expanded pediatric inclusion in diagnostic criteria and trials, and improved outcomes with high-efficacy therapies.
The doctors outlined their research approaches—Dr. Banwell’s integrative, imaging-focused team science [00:08:45] and Dr. Chen’s clinical research including a project on IVIG duration for relapsing pediatric MOGAD [00:11:00]. The discussed their multidisciplinary clinic supports, continuity into adulthood within one health system, and emphasis on availability, collaboration, community resources, and hope for the future [00:13:35].
View the medical profile of Dr. Brenda Banwell:
https://profiles.hopkinsmedicine.org/provider/brenda-banwell/3154504
View the medical profile of Dr. Haiwen Chen:
https://profiles.hopkinsmedicine.org/provider/haiwen-chen/2703784
Brenda Banwell is the director of the Department of Pediatrics, as well as pediatrician-in-chief and co-director of Johns Hopkins Children’s Center, where she helps manage the hospital’s many clinical and research centers. Dr. Banwell is a renowned expert in the research and treatment of pediatric multiple sclerosis (MS) and other neuroimmune disorders. She specializes in and studies the use of neuroimaging to assess the clinical and cognitive impact of the conditions, as well as the function of the immune system in children with these disorders. Dr. Banwell has published more than 250 manuscripts in high-impact journals, along with over 25 book chapters. In addition, she has over 200 national and international invited lectureships and visiting professorships.
An advocate for pediatric multiple sclerosis needs and research, Dr. Banwell serves as chair of the International Medical and Scientific Board of the Multiple Sclerosis International Federation, and the Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD) International Research Consortium. She is also chair of the pediatric committee of the National Institutes of Health NeuroNEXT program, which conducts studies on treatments for neurological diseases through academic, private, and industry collaborations. Dr. Banwell currently serves as past-chair of the International Pediatric Multiple Sclerosis Study Group.
Dr. Haiwen Chen is a pediatric neurologist who specializes in caring for children with pediatric onset neuroinflammatory and neuroinfectious diseases, with particular interests in demyelinating disorders and myelitis. Dr. Chen earned her MD and PhD from the University of Maryland School of Medicine. She completed a pediatric neurology residency and fellowship training in neuroimmunology and neurological infectious diseases at The Johns Hopkins Hospital. Dr. Chen’s research training focused on understanding synaptic structure and function using molecular biology and microscopy techniques. Her current research focuses on understanding how oligodendrocyte affect synaptic function in health and disease with the goal of developing strategies for preserving and restoring synaptic function to treat cognitive dysfunction in demyelinating disorders.
00:00 Introduction
01:49 Why Child Neurology
04:24 Choosing Neuroimmunology
08:45 Dr. Banwells Research Focus
11:00 Dr. Chens Research Focus
13:35 Clinic Team and Referrals
17:24 Continuity Into Adulthood
20:55 Self Care and Balance
25:26 Advice for New Families
28:57 Hope Through Collaboration
33:45 Closing Community Meets Clinic 306. Drs. Brenda Banwell and Haiwen Chen](https://i.ytimg.com/vi/4GVymdo2ePc/mqdefault.jpg)
![2024 RNDS | Aging: What to Expect?
At the 2024 RNDS, Dr. Carlos A. Pardo and Dr. Michael Levy introduced the topic of aging in rare neuroimmune disorders [00:01:10]. The biology of aging, including genetic factors, cellular senescence, and oxidative stress was explained in detail [00:00:50]. The role of environmental and epigenetic factors in aging and their impact on conditions like myelitis and neuromyelitis optica spectrum disorder (NMOSD) was discussed [00:04:40]. Finally, the session covered various management strategies for aging-related symptoms and answered audience questions about specific concerns related to aging and neurological diseases [00:10:12]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction to Aging in Neuroimmune Disorders
00:50 Understanding the Biology of Aging
01:43 Genetic and Cellular Factors in Aging
04:40 Environmental and Epigenetic Influences
05:45 Impact of Aging on Neurological Health
08:25 Inflammation and Immune System Aging
10:12 Managing Aging in Neuroimmune Disorders
12:26 Audience Questions 2024 RNDS | Aging: What to Expect?](https://i.ytimg.com/vi/51eCaT5wyxo/mqdefault.jpg)

![2024 RNDS | Cannabis Use in Rare Neuroimmune Disorders
At the 2024 RNDS, Melanie Delgado and Dr. Anastasia Vishnevetsky discussed their cross-sectional survey study on cannabis use among individuals with CNS neuroinflammatory diseases, emphasizing the lack of existing literature on the subject and detailing the studys objectives and methodology [00:01:05]. The study surveyed 267 respondents, analyzing demographics, reasons for cannabis use, targeted symptoms, frequency and methods of use, effectiveness, and side effects [00:02:27]. Findings revealed that most respondents used cannabis primarily for sleep disturbances, muscle spasms, pain, and anxiety, with oral consumption being the most common method [00:03:57]. In conclusion, Melanie highlighted the need for more prospective research to guide safe and appropriate cannabis use for patients with these conditions [00:08:34]. Melanie and Dr. Vishnevetsky also answered questions from the audience [00:10:48]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Acknowledgements
00:41 Study Motivation and Background
01:40 Methodology and Study Design
02:27 Study Objectives and Participant Demographics
03:57 Cannabis Use Patterns and Effectiveness
06:58 Side Effects and Barriers to Cannabis Use
08:34 Patient-Provider Communication and Conclusions
10:48 Q&A Session 2024 RNDS | Cannabis Use in Rare Neuroimmune Disorders](https://i.ytimg.com/vi/5FRlANElDfs/mqdefault.jpg)
![2024 RNDS | Social Determinants of Health in TM
At the 2024 RNDS, Ka-Ho Wong discussed the project on social determinants of health in myelopathy and transverse myelitis, highlighting its funding by SRNA [00:00:10]. Ka-Ho explained the five categories of social determinants of health as defined by Healthy People 2030 and their relevance to neurology [00:01:05]. Various studies were cited, including ones focusing on neighborhood disadvantage, stress, and socioeconomic status affecting conditions like neuromyelitis optica spectrum disorder (NMOSD) [00:02:30]. Ka-Ho also delved into ongoing and future research projects to better understand the impact of social determinants on neuroimmune disease outcomes [00:05:45]. Finally, Ka-Ho answered questions from the audience [00:11:25]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Acknowledgements
00:27 Understanding Social Determinants of Health
01:26 Social Determinants in Neurology
02:18 Research on Rare Neuroimmune Disorders
04:03 Transverse Myelitis Outcome Project
06:32 Survey Studies and Preliminary Results
11:25 Q&A Session 2024 RNDS | Social Determinants of Health in TM](https://i.ytimg.com/vi/5PnUvATDr0I/mqdefault.jpg)
![2024 RNDS | Disability: Adapting to and Embracing Disability
At the 2024 RNDS, Dr. Cyrena Gawuga discussed the differences between the medical and social models of disability and emphasized societys role in accommodating individuals with disabilities [00:00:24]. She shared her personal journey and how it shaped her understanding of disability [00:03:09]. Dr. Gawuga explained the value of inspiration and advocated for broader societal acceptance and support [00:07:36]. The talk concluded with answering questions from the audience, and encouraging individuals to embrace their identity and accomplishments without seeking external validation [00:10:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
00:00 Introduction and Speaker Background
00:24 Understanding the Concept of Disability
01:23 Medical vs. Social Model of Disability
03:09 Personal Journey and Realizations
06:16 Disability Advocacy and Social Change
07:36 Challenging Inspirational Narratives
10:34 Embracing Disability Pride
17:20 Conclusion and Final Thoughts
19:20 Audience Questions 2024 RNDS | Disability: Adapting to and Embracing Disability](https://i.ytimg.com/vi/6GP6E3nSM_Q/mqdefault.jpg)
![2026 RNDS | Closing Remarks
In this closing session from the 2026 Rare Neuroimmune Disorders Symposium (RNDS), Michael Levy, MD, PhD, of Massachusetts General Hospital, and SRNA Executive Director GG deFiebre closed the three-day symposium [00:00:05]. Dr. Levy led applause for the speakers, the SRNA staff who put the event on, and everyone who stayed to the end [00:00:05]. GG thanked those attending online and in person, and the presenting sponsors Alexion, Amgen, Genentech and UCB, along with Kennedy Krieger and Grapevine [00:01:00]. Attendees used their phones to share one-word takeaways, including empowerment, validation, hope and community [00:01:39]. They also answered how they felt after three days, and Dr. Levy ended with one word of his own: thank you [00:03:05].
Michael Levy, MD, PhD, is an Associate Neurologist at Massachusetts General Hospital and Research Director of the Division of Neuroimmunology and Neuroinfectious Disease. He completed the MD/PhD program at Baylor College of Medicine and trained at Johns Hopkins, where he started the Neuromyelitis Optica Clinic and Research Laboratory. In 2019, he moved to Massachusetts General Hospital and Harvard Medical School to develop the research program in neuroimmunology.
00:00 Welcome and Applause
00:34 Thanks to Everyone Who Stayed
01:00 Thanks from SRNA and Sponsors
01:39 Biggest Takeaway Poll
03:05 How Are You Feeling
04:06 One Word for RNDS
04:35 Final Thanks 2026 RNDS | Closing Remarks](https://i.ytimg.com/vi/6HhK0WJurYc/mqdefault.jpg)
![2024 RNDS | NMOSD and MOGAD Clinical Trials
At the 2024 RNDS, Dr. Michael Levy of Massachusetts General Hospital discussed various therapeutic approaches for MOG antibody disease (MOGAD), transverse myelitis (TM), and neuromyelitis optica spectrum disorder (NMOSD), including acute therapy, preventive therapy, regenerative therapy, and symptomatic trials. Details were provided on specific trials such as the rozanolixizumab trial for MOGAD and the use of satralizumab for NMOSD [00:00:58]. Another focus was on a study investigating the impact of a dairy-free diet on MOG antibody levels [00:01:58]. Dr. Levy also mentioned acute treatment trials and the potential impact of cannabis-based products on improving quality of life for those diagnosed with NMOSD [00:11:16]. He concluded by answering audience questions [00:15:34]. Please note that the information shared during this session is for informational purposes only and is not medical advice.
You can view the presentation slides here:
https://files.wearesrna.org/symposia/2024_rnds/slides/2024RNDS_Levy.pdf
00:00 Introduction to MOGAD, TM, and NMOSD Trials
00:13 Understanding Acute and Preventive Therapies
00:32 Exploring Regenerative and Symptomatic Therapies
00:58 Current Trials in NMOSD
01:58 MOGAD Trials
02:28 Mechanism of Action: FcRn Blockers
04:19 Trial Design and Enrollment
05:38 Enspryng Trials for MOGAD
07:39 Dairy-Free Diet Study
11:16 Acute Treatment Trials
13:54 Nabiximols for NMOSD Quality of Life
15:28 Audience Questions 2024 RNDS | NMOSD and MOGAD Clinical Trials](https://i.ytimg.com/vi/75Bwop2jNXo/mqdefault.jpg)
![1214. Self Identity and Finding Meaning Following Diagnosis
In this Ask the Expert episode, Krissy Dilger of SRNA spoke with Susan Y. Wegener, LCSW, a licensed clinical social worker, about coping with a chronic diagnosis and its emotional adjustments, referencing Kübler-Ross’ stages of grief [00:03:45]. Susan discussed the importance of self identity transformation post-diagnosis and the need for patience and self-compassion in finding new ways to move forward [00:08:34]. The value of inner strength, setting priorities, and support groups for reducing isolation and fostering compassion was emphasized [00:15:20]. The discussion concluded with a focus on post-traumatic growth, highlighting greater life appreciation and mental flexibility as key coping strategies [00:16:01].
Susan Y. Wegener, LCSW is a licensed clinical social worker who maintains a private psychotherapy practice in Austin, TX. Her clinical practice specializes in work with individuals coping with chronic medical diagnoses. She completed her undergraduate degree, in Psychology, from Skidmore College, Saratoga Springs N.Y., 1993 and her graduate degree, in Social Work from Columbia University, New York City in 1995. In addition to her private practice, she has worked in multiple medical settings throughout her career and helped to empower and support individuals from diagnosis through the adjustment process. She became a Partner in Care for the National Multiple Sclerosis Society in 2017 and is passionate about her work with individuals diagnosed with MS and various other neurological diagnoses. In her free time, she enjoys singing in a local chorus, cooking, swimming, and spending time with her family. Please see the following link to her workbook “Hold on to Hope.”
https://www.amazon.com/Hold-Hope-Overview-Strategies-Chronic/dp/1512218715
00:00 Introduction to the Podcast
00:37 Meet the Expert: Susan Wagner
01:00 Coping with a Chronic Diagnosis
01:47 The Emotional Adjustment Process
05:36 Understanding Self Identity Post-Diagnosis
08:34 Dealing with Denial
10:39 Coping Strategies for Shifting Self Identity
14:08 Finding Meaning and Purpose
14:26 Exploring the Impact of Diagnosis
15:25 Reflecting on Values and Strengths
16:06 Coping Strategies for Finding Meaning
16:29 The Role of Relationships and Support Systems
18:05 Prioritizing Self-Care and Realistic Goals
20:04 Finding Meaning in Suffering
20:15 The Concept of Post-Traumatic Growth
24:52 The Importance of Stillness and Self-Compassion
28:31 Mental Flexibility and Creative Thinking
30:02 Conclusion and Final Thoughts 1214. Self Identity and Finding Meaning Following Diagnosis](https://i.ytimg.com/vi/8-4AgHzzMrA/mqdefault.jpg)
![Community Meets Clinic 304. Dr. Ayşe Altıntaş
The Community Meets Clinic podcast series introduces clinicians and healthcare personnel specializing in rare neuroimmune disorders. In this episode, Krissy Dilger of SRNA spoke with Dr. Ayşe Altıntaş, Professor of Neurology at Koç University School of Medicine in Istanbul, Turkey, which has been designated as a Center of Excellence in Rare Neuroimmune Disorders. Dr. Altıntaş described the unmet needs in rare neuroimmune disorders and noted her role on an international panel developing updated NMOSD diagnostic criteria [00:03:40]. She outlined current research on mechanisms of optic neuritis, pregnancy complications and aquaporin-4 antibodies, and developing accessible biomarkers beyond CSF with a future goal of remote monitoring [00:06:01]. Dr. Altıntaş also explained Koç University’s multidisciplinary demyelinating disease center model, emphasizing coordinated consultations, advanced MRI capabilities, shared decision-making, and the value of specialized centers, while expressing hope due to rapid advances in biomarkers and targeted therapies [00:11:43]. You can view the medical profile of Dr. Ayşe Altıntaş here:
https://www.kuh.ku.edu.tr/doctors/ayse-altintas
Ayşe Altıntaş, MD is a professor of neurology at Koç University School of Medicine in Istanbul, Türkiye. She graduated from Ege University Faculty of Medicine in 1986 and completed her neurology residency there in 1992. She received early training in neuroimmunology as a fellow at Mayo Clinic under Prof. Moses Rodriguez and later continued her research at Mayo Clinic with Prof. Claudia Lucchinetti and Prof. Brian Weinshenker, focusing on the animal model, immunopathology, and imaging correlates of multiple sclerosis.
Prof. Altıntaş served at Istanbul University Cerrahpaşa School of Medicine for 23 years before joining Koç University in 2018, where she established a neuroimmunology laboratory and continues to lead clinical and translational research. Her work focuses on multiple sclerosis, neuromyelitis optica spectrum disorders (NMOSD) and MOG antibody-associated diseases (MOGAD), with an emphasis on biomarkers and disease mechanisms. She is actively involved in international organizations, including BioMS-eu, The MOG Project, Siegel Rare Neuroimmune Association (SRNA), MEDEN, the MSBase Scientific Leadership Group, and the Guthy-Jackson Charitable Foundation International Scientific Consortium.
00:00 Welcome and Guest Intro
01:39 Why Neurology
03:40 Choosing Rare Disorders
06:01 Current Research Projects
11:43 Clinic Team and Workflow
15:48 Advanced Imaging and Coordination
17:20 Self Care and Balance
20:20 Advice for New Patients
22:17 Hope for the Future
24:34 Closing Community Meets Clinic 304. Dr. Ayşe Altıntaş](https://i.ytimg.com/vi/8Ih_dfaRGS0/mqdefault.jpg)